Imaging Multiparametric/Multimodality for Lungcancer

Study Overview
=================
Brief Summary
-----------------
To build an imaging biobank of 200 patients with lungcancer, including pathologic and molecular characteristics of the tumor (mutational status, circulating DeoxyriboNucleic Acid (DNA) from serum biobank…), staging of the cancer (according to the new 2016 Tumor Node Metastasis (TNM) status, the table that classify non-small cell lungcancer) and follow-up informations (Response to first-line treatment (Response Evaluation Criteria in Solid Tumors (RECIST)), disease-free survival, 1-3 years survival). To propose a simple severity scoring system based on tumor features such as size, doubling time (if available), location, amount of enhancement and necrosis. Such approach has been proposed for glioma evaluation (Visually Accessible Rembrandt Images (VASARI)) but is not available for the lung. The objective is to do better than the Tumor Node Metastasis (TNM) staging. To develop and evaluate an IntraVoxel Incoherent Motion (IVIM) protocol for lungcancer evaluation.

Official Title
-----------------
Imaging Multiparametric/Multimodality (Magnetic Resonance Imaging Combined With Positron Emission Tomography) for Lungcancer

Conditions
-----------------
Lungcancer

Intervention / Treatment
-----------------
* Other: Magnetic Resonance Imaging (MRI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults over 18 years High suspicion of lungcancer confirmed Tumor > 2 cm Incomplete cerebral staging or not yet realized in the initial consultation of screening Exclusion Criteria: Lungcancer medical history During Pregnancy Contraindications to MRI Patient not able to understand the information of the protocol, taking into account the state of the brain Patient unable to keep lying in MRI the necessary time

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Magnetic Resonance Imaging (MRI)<br>Thoracic Magnetic Resonance Imaging (MRI) | Other: Magnetic Resonance Imaging (MRI)<br>* Chest MRI during the MRI cerebral 2 tubes of blood taken during the medical visit<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Event-free survival of patients with lungcancer |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 3 months, 1 year, 2 years and 3 years | 
| Number of patients by histologic subtypes |  | 3 months, 1 year, 2 years and 3 years | 
| Number of patients by mutational profile |  | 3 months, 1 year, 2 years and 3 years | 
| Number of patients with metastases |  | 3 months, 1 year, 2 years and 3 years | 
| Number of patients with brain metastases |  | 3 months, 1 year, 2 years and 3 years | 
| Number of metastases by patient |  | 3 months, 1 year, 2 years and 3 years | 
| Therapeutic responses assessed by scanner/MRI and/or Positron Emission Tomography (PET) based on consensus criteria (RECIST 1.1 and PET Response Criteria in Solid Tumors (PERCIST)) |  | 3 months, 1 year, 2 years and 3 years |